Trial · NCT00968812
Adverse events1,008
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,008
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Canagliflozin 100 mg: Baseline to Week 52 | 24 | 483 | |
| other | Diarrhoea | Gastrointestinal disorders | Canagliflozin 300 mg: Baseline to Week 52 | 33 | 485 | |
| other | Diarrhoea | Gastrointestinal disorders | Glimepiride: Baseline to Week 52 | 29 | 482 | |
| other | Diarrhoea | Gastrointestinal disorders | Canagliflozin 100 mg: Baseline to Week 104 | 25 | 482 | |
| other | Diarrhoea | Gastrointestinal disorders | Canagliflozin 300 mg: Baseline to Week 104 | 39 | 485 | |
| other | Diarrhoea | Gastrointestinal disorders | Glimepiride: Baseline to Week 104 | 34 | 482 | |
| other | Nausea | Gastrointestinal disorders | Canagliflozin 100 mg: Baseline to Week 52 | 16 | 483 | |
| other | Nausea | Gastrointestinal disorders | Canagliflozin 300 mg: Baseline to Week 52 | 25 | 485 | |
| other | Nausea | Gastrointestinal disorders | Glimepiride: Baseline to Week 52 | 13 | 482 | |
| other | Nausea | Gastrointestinal disorders | Canagliflozin 100 mg: Baseline to Week 104 | 20 | 483 | |
| other | Nausea | Gastrointestinal disorders | Canagliflozin 300 mg: Baseline to Week 104 | 27 | 485 | |
| other | Nausea | Gastrointestinal disorders | Glimepiride: Baseline to Week 104 | 19 | 482 | |
| other | Nasopharyngitis | Infections and infestations | Canagliflozin 100 mg: Baseline to Week 52 | 33 | 483 | |
| other | Nasopharyngitis | Infections and infestations | Canagliflozin 300 mg: Baseline to Week 52 | 37 | 485 | |
| other | Nasopharyngitis | Infections and infestations | Glimepiride: Baseline to Week 52 | 37 | 482 | |
| other | Nasopharyngitis | Infections and infestations | Canagliflozin 100 mg: Baseline to Week 104 | 47 | 483 | |
| other | Nasopharyngitis | Infections and infestations | Canagliflozin 300 mg: Baseline to Week 104 | 55 | 485 | |
| other | Nasopharyngitis | Infections and infestations | Glimepiride: Baseline to Week 104 | 51 | 482 | |
| other | Upper respiratory tract infection | Infections and infestations | Canagliflozin 100 mg: Baseline to Week 52 | 17 | 483 | |
| other | Upper respiratory tract infection | Infections and infestations | Canagliflozin 300 mg: Baseline to Week 52 | 27 | 485 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00968812/events